Can You Take Wegovy for Just 3 Months?

What does three months on Wegovy actually look like clinically?

It helps to understand where three months sits on the treatment timeline. Wegovy starts at 0.25 mg and is titrated upward roughly every four weeks: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg as the standard maintenance dose. That progression takes around 16 to 20 weeks for most people, which means at the three-month mark (twelve or thirteen weeks in) many patients are still stepping through the lower doses. The maintenance dose, where the main therapeutic effect is established, is only just being reached, or hasn't been reached at all.

In practical terms, three months is the adjustment period. The body is settling, the gastrointestinal side effects that many people notice early (nausea, loose stools, changes in appetite) are usually at their most noticeable during these earlier steps, and appetite suppression tends to become more consistent once the maintenance dose has had time to work. If you are wondering whether you can take Wegovy for one month and see meaningful results, the short answer is that one month typically covers only the very first titration step, before the medicine has had a chance to work fully. You can get a sense of how you respond, but the fuller picture comes later.

You can read a broader overview of how Wegovy works and what to expect on our Wegovy information page.

Does the licensed guidance set a minimum or maximum time on Wegovy?

The UK licence for Wegovy does not specify a fixed minimum treatment period. It is licensed for long-term weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition, used alongside dietary changes and increased activity. There is no prescription rule that says you must stay on it for a set number of months.

NICE's appraisal of semaglutide for weight management (Technology Appraisal TA875) does however recommend use for a maximum of two years within a specialist weight management service. NICE also advises that if less than five per cent weight loss has occurred after six months at the maintenance dose, continuing should be reviewed. So rather than a minimum, there is a review point built into good clinical practice.

What this means for someone asking about three months: stopping earlier than planned is not prohibited, but it should be a conversation with your prescriber. They will want to understand why (whether it is side effects, life circumstances, cost, or something else) because the answer shapes what happens next. A related question our prescribers are often asked is whether Wegovy can be taken once a month rather than weekly, and the straightforward answer is that its licensed dosing schedule is weekly, so monthly injections would not replicate the clinical effect.

What happens to weight if you stop Wegovy after three months?

This is a question our prescribers hear most weeks, and it deserves a straight answer. Semaglutide works partly by reducing appetite through GLP-1 receptor activity; when the medicine is stopped, that appetite-suppressing effect fades over the following weeks. Clinical data from the STEP 1 trial, published in the New England Journal of Medicine, showed that much of the weight lost during treatment returned within a year of stopping for participants who had not embedded sustained lifestyle changes alongside the medicine.

People sometimes ask whether taking Wegovy for just one month is worthwhile, and the clinical picture suggests that after only three months (mostly spent in titration) the weight change seen is likely to be modest, and the habits that support long-term weight management may not yet be firmly established. Stopping is not dangerous in the way stopping some medicines is, but it is worth being clear-eyed about what comes next. If pausing rather than stopping is on the table, a prescriber can advise on how to manage that transition.

Our frequently asked questions cover related questions about restarting and pausing treatment.

Who does Wegovy's licensing actually cover, and does three months change that?

Eligibility for Wegovy does not change based on intended duration. The licence applies to adults with a BMI of 30 or above, or a BMI of 27 or above alongside a qualifying weight-related condition such as high blood pressure, high cholesterol, prediabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Pregnancy, breastfeeding and trying to conceive are circumstances where the medicine is not recommended; it is not licensed for people under 18.

For the purposes of a private prescription, the prescriber assesses all of this at the consultation stage and again at each repeat, not once and never again. If you are considering treatment and wondering whether your BMI puts you in the eligible range, the Wegovy BMI eligibility page covers the qualifying thresholds in detail. And if you are at the earlier stages of thinking about whether this is right for you at all, the guide to Wegovy suitability is worth reading first.

Duration is a clinical question, not an administrative one. If three months is what you can commit to right now, that conversation belongs with a prescriber who knows your full picture. To have that conversation with our clinical team, check your eligibility with a free consultation.